Ask AI
ProCE Banner Activity

Phase I Trial of the KRAS G12D Inhibitor INCB161734 in Previously Treated KRAS G12D–Mutant Advanced Solid Tumors

Conference Coverage
Slideset

A phase I study of the KRAS G12D inhibitor INCB161734 demonstrated manageable safety and promising clinical efficacy in patients with previously treated KRAS G12D–mutant advanced solid tumors including preliminary antitumor activity in patients with PDAC. 

Released: November 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly